BRAF and melanoma: The discovery of a BRAF mutation, consisting of the substitution of V600E valine for glutamic acid at codon 600 that constitutively activates the MAPK (mitogen-activated protein kinase) pathway in more than 60% of melanomas, led to the use of BRAF inhibitors (BRAFi) targeting this mutation [6].